Influencing Factors for Erectile Dysfunction of Young Adults with No Response to PDE5i

Abstract

Erectile dysfunction (ED) is a common male disorder. Although orally-administered phosphodiesterase type 5 inhibitors (PDE5 inhibitors) are now recognized as the primary pharmacological treatment method for ED, 20%–30% of the patients treated with PDE5 inhibitors exhibit no significant effects. This study aims to investigate the influencing factors of ED in young adults with no response to PDE5 inhibitors. ED patients who would take PDE5 inhibitors were included and investigated with a questionnaire. Patients with no response to PDE5 inhibitors (tadalafil and sildenafil) served as study group, and those with response to PDE5 inhibitors as control group. Then Chi square test and logistic regression analysis were applied to find the potential influencing factors. In total, 378 ED patients were included. Ninety-three (24.6%) cases were non-responsive to PDE5 inhibitors, and the remaining 285 (75.4%) responded to PDE5 inhibitors. In multiple logistic regression analysis, we found that history of drinking (OR=3.152; 95%CI 1.672–6.975), spousal noncooperation (OR=2.994; 95%CI 1.589–5.638), number of fixed sex partners (OR=0.358; 95%CI 0.132–0.651), duration of ED (OR=3.356; 95%CI 1.352–8.333), and depression (OR=3.689; 95%CI 1.579–8.979) could be the influencing factors for ED patients’ non-response to PDE5 inhibitors. In conclusion, history of drinking, spousal noncooperation, number of fixed sex partner, long duration of ED, and depression could be the influencing factors for ED patients’ non-response to PDE5 inhibitors. Patients and doctors should pay attention to these factors.

Keywords

erectile dysfunction / PDE5 inhibitors / influencing factor

References

[1] NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA, 1993, 270(1): 83-90

[2] UckertS, MayerME, StiefCG, et al.. The future of the oral pharmacotherapy of male erectile dysfunction: things to come. Expert Opin Emerg Drugs, 2007, 12(2): 219-228

[3] European Association of Urology Guidelines. 2017 edition. 2017

[4] BaconCG, MittlemanMA, KawachiI, et al.. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med, 2003, 139(3): 161-168

[5] VicenziniE, AltieriM, MichettiPM, et al.. Cerebral vasomotor reactivity is reduced in patients with erectile dysfunction. Eur Neurol, 2008, 60(2): 85-88

[6] FeldmanHA, JohannesCB, DerbyCA, et al.. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med, 2000, 30(4): 328-338

[7] MinerMM, KuritzkyL. Erectile dysfunction: a sentinel marker for cardiovascular disease in primary care. Cleve Clin J Med, 2007, 74(Suppl 3): S30-S37

[8] FisherWA, EardleyI, MccabeM, et al.. Erectile dysfunction (ED) is a shared sexual concern of couples II: association of female partner characteristics with male partner ED treatment seeking and phosphodiesterase type 5 inhibitor utilization. J Sex Med, 2009, 6(11): 3111-3124

[9] Hatzimouratidis K. Reply to Pero Bokarica’s letter to the editor re: K. Hatzimouratidis, I. Eardley, F. Giuliano, I. Moncada, A. Salonia. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. European Association of Urology Website. http://uroweb.org/guideline/male-sexual-dysfunction/. Updated 2015. Eur Urol, 2015,68 (4):e78

[10] MulhallJP. Penile rehabilitation following radical prostatectomy. Curr Opin Urol, 2008, 18(6): 613-620

[11] PorstH, GiulianoF, GlinaS, et al.. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol, 2006, 50(2): 351-359

[12] LeeJW, ParkHJ, ParkNC. Serum High-Sensitivity C-Reactive Protein Levels and Response to 5 mg Tadalafil Once Daily in Patients With Erectile Dysfunction and Diabetes. Korean J Urol, 2013, 54(12): 858-864

[13] MoncadaI, Martinez-SalamancaJI, AllonaA, et al.. Current role of penile implants for erectile dysfunction. Curr Opin Urol, 2004, 14(6): 375-380

[14] LeeCH, KimHS, GooMJ, et al.. Chronic administration of udenafil, a selective phosphodiesterase type 5 inhibitor, promotes erectile function recovery in an animal model of bilateral cavernous nerve crush injury. J Sex Med, 2011, 8(5): 1330-1340

[15] WashingtonSR, ShindelAW. A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. Drug Des Devel Ther, 2010, 4: 159-171

[16] LiuDF, JiangH, HongK, et al.. Epidemiological changes of ED patients: investigations in 11 Chinese cities during the past 5 years. Zhonghua Nan Ke Xue (Chinese), 2009, 15(8): 724-726

[17] KimSC, LeeYS, SeoKK, et al.. Reasons and predictive factors for discontinuation of PDE-5 inhibitors despite successful intercourse in erectile dysfunction patients. Int J Impot Re, 2014, 26(3): 87-93

[18] BecharaA, CasabeA, De BonisW, et al.. Twelve-Month Efficacy and Safety of Low-Intensity Shockwave Therapy for Erectile Dysfunction in Patients Who Do Not Respond to Phosphodiesterase Type 5 Inhibitors. Sex Med, 2016, 4(4): e225-e232

[19] HakimL, Van der AaF, BivalacquaTJ, et al.. Emerging tools for erectile dysfunction: a role for regenerative medicine. Nat Rev Urol, 2012, 9(9): 520-536

[20] LiuY, SongH, WangT, et al.. Determinants of tobacco smoking among rural-to-urban migrant workers: a cross-sectional survey in Shanghai. BMC Public Health, 2015, 15: 131

[21] SeredaY, DembitskyiS. Validity assessment of the symptom checklist SCL-90-R and shortened versions for the general population in Ukraine. BMC Psychiatry, 2016, 16(1): 300

[22] RobertsN, ParkerKC, DagnoneM. Comparison of Clinical Diagnoses, NIMH-DISC-IV Diagnoses and SCL-90-R Ratings in an Adolescent Psychiatric Inpatient Unit: A Brief Report. Can Child Adolesc Psychiatr Rev, 2005, 14(4): 103-105

[23] BarbonettiA, CavalloF, FelzaniG, et al.. Erectile Dysfunction is the Main Determinant of Psychological Distress in Men with Spinal Cord Injury. J Sex Med, 2012, 9(3): 830-836

[24] AghighiA, GrigoryanVH, DelavarA. Psychological determinants of erectile dysfunction among middle-aged men. Int J Impot Res, 2015, 27(2): 63-68

[25] JuanYS, LongCY, ChouYH, et al.. Sexual Dysfunction in Men with Chronic Pelvic Pain Syndrome. Incontinence Uff06 Pelvic Floor Dysfunction, 2011, 5(2): 31-34

[26] ZengHQ, ZhangCH, LuGC. Psychological factors and erectile function in men with refractory chronic prostatitis. Zhonghua Nan Ke Xue (Chinese), 2008, 14(8): 728-730

[27] CairoliC, ReyesLA, HennegesC, et al.. PDE5 inhibitor treatment persistence and adherence in Brazilian men: post-hoc analyses from a 6-month, prospective, observational study. Int Braz J Urol, 2014, 40(3): 390-399